Molgeom Uno (Molsidomine)

Molsidomine, the active ingredient in Molgeom Uno, is a nitric oxide donor presented as an oral dosage form for oral use. It is employed to manage stable angina pectoris in adult patients, helping to alleviate chest pain by improving coronary blood flow. The drug is metabolized to l‑citrulline, which releases nitric oxide, producing vasodilation and reducing cardiac preload and afterload.

GNH USA supplies Molgeom Uno as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Molsidomine acts as a nitric oxide donor to relieve myocardial ischemia in angina‑related conditions.

- Stable angina pectoris: reduces frequency and severity of chest pain episodes - Chronic stable angina: improves exercise tolerance and delays onset of angina during physical activity - Ischemic heart disease: decreases myocardial oxygen demand by lowering cardiac preload and afterload

Molsidomine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache - Flushing - Dizziness - Nausea - Hypotension

Serious or Rare Side Effects: - Severe hypotension - Syncope - Allergic reactions (rash, urticaria, anaphylaxis) - Worsening angina or myocardial infarction (rare)

When prescribing molsidomine, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor blood pressure: check baseline and periodic measurements to detect hypotension - Avoid use in severe hypotension: contraindicated in patients with markedly low blood pressure - Caution in heart failure: assess cardiac function before initiation - Assess hepatic function: dose adjustment may be required in severe liver impairment - Do not discontinue abruptly: tapering may be needed to avoid rebound angina - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight

Molsidomine can interact with other agents that affect vascular tone or blood pressure.

Major Interactions (Avoid): - Nitrate donors (e.g., nitroglycerin, isosorbide dinitrate): additive vasodilation may cause severe hypotension - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil, vardenafil): risk of profound hypotension - Sodium nitroprusside: combined effect may lead to excessive blood pressure drop

Moderate Interactions (Monitor Closely): - Antihypertensive drugs (ACE inhibitors, ARBs, calcium channel blockers): may enhance blood pressure‑lowering effect - Beta‑blockers: may mask tachycardic response to hypotension - Alcohol: can potentiate hypotensive effects, requiring caution